Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can allergy shots work as well for kids as adults? new study aims to find out.

NCT ID NCT05186025

Disease control Sponsor: Allergy Therapeutics Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This 5-year study is looking at how well a year-round allergy treatment (MATA trees or MATA grass) works for children and adults with pollen allergies, including hay fever and mild asthma. Researchers want to see if the treatment is as effective in kids as it is in adults. About 320 participants aged 5 and older will track their symptoms and medication use during pollen seasons.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
MATA trees or MATA grass (modified allergen extracts adsorbed to microcrystalline tyrosine)
What this could lead to
If successful, this could confirm that a shorter, year-round allergy treatment works equally well for children and adults, offering a convenient option for managing pollen allergies.
What could go wrong
This is an observational study, not a controlled trial, so results may be less reliable. It also does not test a new treatment, but rather compares how well an existing one works in different age groups.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

320 people

The number who actually took part.

Started

Nov 2020

Expected to finish

Oct 2026

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adults, adolescents and children from the age of 5 on, who are going to be treated with TA Bäume or TA Gräser.

Ages

5 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients from 5 years of age who are treated with TA Gräser top or TA Bäume top due to rhinitis, conjunctivitis and/or mild to moderate bronchial asthma, which are caused by an IgE-mediated allergy to grass and rye pollen or birch, alder and hazel pollen according to the respective SmPC. * Patients will only be included in this study after the decision on the treatment has been made. Exclusion Criteria: * History of allergen-specific immunotherapy (SIT) for trees or grass within the last 5 years * If it´s intended to treat the patient with only a preseasonal therapy * A patient should also not be included in the presence of any of the conditions listed in the respective SmPC

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Allergic asthma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

allergic asthma allergic disease allergic rhinitis atopic conjunctivitis Conjunctivitis, Allergic seasonal allergic rhinitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Allergic asthma Allergic conjunctivitis Allergic rhinitis due to pollen

Contacts and locations

Locations

  • Universitätsklinikum Augsburg

    Augsburg, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.